The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Slideshows|January 17, 2020
RA Quiz: How well does upadacitinib fare as RA treatment?
Author(s)Katie Robinson
The JAK inhibitor upadacitinib was approved last August for the treatment of moderate to severe rheumatoid arthritis. In this quiz, we focus on findings from a recent phase three clinical trial that tested different doses of this new oral medication. Test your knowledge of upadacitinib in this quiz.
Advertisement
The JAK inhibitor upadacitinib was approved last August for the treatment of moderate to severe rheumatoid arthritis. In this quiz, we focus on findings from a recent phase three clinical trial that tested different doses of this new oral medication. Test your knowledge of upadacitinib in this quiz.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement